Evidence map›Paper›PMID 35492086›Full record

ArticleRSC advances2020

Superior antitumor effect of self-assembly supramolecular paclitaxel nanoparticles.

Na Yu, Jun Li, Yuan Zhang, Dan Ding, Xiaolin Li, Huae Xu

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Na YuDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University Nanjing 210029 China xuhuae@njmu.edu.cn.
Jun LiState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials Ministry of Education and College of Life Sciences Nankai University Tianjin 300071 China.
Yuan ZhangDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University Nanjing 210029 China xuhuae@njmu.edu.cn.
Dan DingState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials Ministry of Education and College of Life Sciences Nankai University Tianjin 300071 China.ORCID https://orcid.org/0000-0003-1873-6510
Xiaolin LiDepartment of Geriatric Gastroenterology, Center of Neuroendocrine Tumor, The First Affiliated Hospital of Nanjing Medical University Nanjing 210029 China lxl@njmu.edu.cn.
Huae XuDepartment of Pharmaceutics, School of Pharmacy, Nanjing Medical University Nanjing 210029 China xuhuae@njmu.edu.cn.ORCID https://orcid.org/0000-0001-9124-303X
Nanjing Medical University · CNNankai University · CNEuropean Neuroendocrine Tumor Society · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paclitaxel (Ptx), a microtubule depolymerization inhibitor, is one of the first-line regimens in lung cancer chemotherapy. However, the poor solubility of Ptx, as well as hypersensitivity of the solvent Cremphor EL, severely limits its clinical application. Here we developed a drug-polymer conjugate of Ptx-SA-PEG, in which amphiphilic copolymers poly(ethylene glycol) (PEG) and Ptx were conjugated by succinic acid (SA). The Ptx-SA-PEG polymers self-assemble into nanoparticles (Ptx-NPs) for efficient delivery of Ptx; cell count kit-8 assay and clonogenic assay were used to analyze the antitumor effect of Ptx-NPs. Acridine orange/ethidium bromide double staining, apoptosis analysis and western blot were measured to explore the apoptotic cell death after Ptx-NPs or free Ptx treatment. Subcutaneous xenograft models were practiced to estimate its tumor cytotoxicity and nonspecific side effects

Identifiers

PMID35492086
PMCPMC9051418
OpenAlexW3014304595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.